Active ingredients: ofatumumab
What it is used for
1. Previously Untreated CLL: ARZERRA is indicated, in combination with chlorambucil or bendamustine, for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and are inappropriate for fludarabine-based therapy.,2. Refractory CLL: ARZERRA, as a single agent, is indicated for the treatment of patients chronic lymphocytic leukaemia (CLL) refractory to fludarabine and alemtuzumab.
How to take it
The way to take this medicine is: Intravenous Infusion.
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Do not Freeze
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
A clear to hazy, colourless to pale yellow liquid, pratically free of visible particles.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient ofatumumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems